It's the end of an era at Amazon. In line with the release of its quarterly earnings, the company on Tuesday announced that founder Jeff Bezos will step down as CEO and assume the role of executive chair in the third quarter of 2021.
Andy Jassy, currently the CEO of Amazon Web Services, which has helped drive profits for the global e-commerce giant in recent years, will take over the top spot.
"Amazon is what it is because of invention," said Bezos in the release. "We do crazy things together and then make them normal. We pioneered customer reviews, 1-Click, personalized recommendations, Prime's insanely-fast shipping, Just Walk Out shopping, the Climate Pledge, Kindle, Alexa, marketplace, infrastructure cloud computing, Career Choice, and much more."
The company also delivered its best quarter ever by revenue with $125.56 billion coming out of the holiday season, compared with $87.4 billion in the fourth quarter of 2019.
In a letter to employees that was published on the company's blog, Bezos explained what he will focus on in his new role and commended his replacement.
"In the Exec Chair role, I intend to focus my energies and attention on new products and early initiatives," he wrote. "Andy is well known inside the company and has been at Amazon almost as long as I have. He will be an outstanding leader, and he has my full confidence."
Smoke that filled the cabin of a Delta flight as it took off from the Atlanta airport in February was so thick the led flight attendant had trouble seeing past the first row of passengers and the pilots donned oxygen masks as a precaution.
Arjan Stephens, President of Nature's Path, discusses the company's origin, how it has evolved today and the interesting product that came from his wedding!
Small business reporter, Gene Marks, joins Cheddar to give analysis on how small businesses are tackling incoming tariffs and how it will affect the consumer.
Babylist CEO Natalie Gordon joins Cheddar to discuss how the website is helping new parents, how to make a registry and how secondhand options are available.
Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.
